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ABSTRACT 
The work seeks to present nanotechnology forms of drug delivery and how it would improve treatment effects to patients. 
Nanotechnology forms of drug delivery not only offer many options for cancer patients using chemotherapeutic drugs, but it also has 
much more alternative uses and this review will seek to present data on the same.  
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Introduction 
In the treatment of cancer, different forms of 
chemotherapeutic drugs are used. The drugs have a 
significant advantage for patient therapy but they have 
some disadvantages as well. They are toxic. They have poor 
tissue selectivity. They have a narrow therapeutic window 
and the continued use of such drugs would lead to drug 
resistance1-9. Toxicity is related to the action of drugs on all 
cells (the cancer cells as well as healthy tissue cells) which 
would result in the death of the healthy tissue cells. A 
selectively targeted drug delivery system is needed to 
improve the prognosis for the patient. This is done with the 
help of nanotechnology. With nanotechnology, it is possible 
to prepare nanoparticles with different size, shapes, 
chemical, and physical properties10-16. Due to their unique 
size, the range of nanoparticles exhibit and more, an 
“enhanced permeability and retention effect” (EPR) is 
observed. This helps the drugs to specifically target and 
accumulate in the tumor cells. The work reviews the 
nanotechnology implementation of drug delivery and its 
efficacy with the help of existing secondary research 
studies.  
Nanotechnology forms of delivery 
Two ways to load the drug in the delivery vehicle in 
nanotechnology forms of delivery are by means of non-
covalent encapsulation and covalent conjugation. In non-
covalent encapsulation, the drug molecules interact with 
the delivery materials by non-covalent bonding, which 
offers advantages of adjusting the ratio of dose and 
multidrug combination. However, the weak non-covalent 
nature would normally lead to instability in drug 
releases17-23. 
In covalent conjugation, both the drugs and the delivery 
materials are chemically bonded together, enabling the 
delivery vehicle as a predictable profile. This is a necessity 
in all treatment plans. The Captothecin CPT, which is 
derived from Chinese tree Camptotheca, exhibits very 
strong cytotoxicity and hence it offers much value for 
cancer treatment. As tested in vivo and in vitro, it is 
identified that CPT is a DNA topoisomerase inhibitor. The 
efficacy of CPT is primarily due to the formation of the 
tertiary complex between topoisomerase, DNA and CPT. 
Rapid accumulation of Cancer DNA is thus terminated. 
Some issues are noticed in the treatment delivery. 
However, for instance, the instability of the e-lactone ring 
in CPT leads to the formation of carboxylate forms that are 
inactive. CPT derivates approved by the FDA are helpful for 
the treatment of cancers of the ovary and colon cancer as 
well. There are pros of using CPT as CPT has a 5-membered 
ring system and this system makes the compound better in 
hydrophobic delivery24-32. 
The advantages of the CPT make it a model compound to be 
used in drug delivery. Especially in the case of hydrophobic 
drug delivery, it is identified that nanoparticles in their 
simple assembly need a hydrophilic structure and, in this 
CPT, it can be used. Natural amino acids and peptides 
structures are used for drug delivery. They do have 
biocompatibility and also reduced systemic toxicity. 
Ethylene glycol is used as a hydrophilic part as well. In self-
assembly of polymers, disulfide bonding is used for the 
purpose of cross-linking. Stability is always an issue in drug 
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delivery and in the use of nanotechnology with some of 
these natural peptide structures, it has been identified that 
stability is corrected to a certain extent. A CPT conjugated 
cross-linked micelles structure with built-in the disulfide 
bond, for instance, can be broken down faster into the 
bloodstream. It diffuses faster into the bloodstream.  
With drug resistance and other serious issues happening in 
traditional treatment methods, the use of nanotechnology 
can aid in better imparting of multiple drug treatment to 
patients. The use of nanotechnology helps address the 
issues of cytotoxicity happening in cancer drug treatments. 
In the case of aggressive cancer, it is necessary to load 
much medicine as a single delivery option in order to slow 
down the rapid abnormal proliferation33-36. However, this 
form of medicine loading, in turn, does damage to the 
person’s health as their normal cells and tissues are 
targeted as well. The efficacy of the chemotherapeutic 
drugs hence has to be re-analyzed. In this context, 
nanotechnology delivery forms become important.  
Additionally, as Yang et al. and Sun et al. highlight, 
nanotechnology does need to be useful in certain medical 
contexts. Yang et al., for instance, argue the efficacy of the 
medicine when it comes to early detection of tumors. Early 
detection of tumors would spell better prognosis for the 
patient. Here nanotechnology is not only playing the role of 
a treatment plan, but it is also playing the role of a 
proactive agent when it comes to treating cancer. Similarly, 
as Sun et al. highlight, the blood-brain BBB barrier that can 
be crossed by nanotechnology helps deliver psychosis 
drugs in a better way to patients without affecting their 
other normal cells. Targeted deliveries and improved and 
overall treatment plans improve as well.  
Conclusion 
Multiple drugs are used with one vehicle such as a nano-
drug delivery method. Nanotechnology holds many 
advantages for chemotherapeutic interventions and 
although scientists have produced various treatments of 
drugs with targeted delivery options, none are as receptive 
as the combined nanotechnology and peptide options. It is 
recommended that more research can be carried out on 
ligand structures and how it could help in targeted drug 
delivery.
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